WBDE(002082)
Search documents
新股发行及今日交易提示-20251013





HWABAO SECURITIES· 2025-10-13 09:16
New Stock Issuance - Marco Polo (Stock Code: 001386) issued at a price of 13.75 on October 13, 2025[1] - New material company (Stock Code: 688585) has a tender offer period from September 29 to October 28, 2025[1] - Zitian (Stock Code: 300280) entered the delisting arrangement period with the last trading day on October 13, 2025[1] Market Alerts - Significant abnormal fluctuations reported for Pinming Technology (Stock Code: 688109) on October 10, 2025[1] - Multiple companies including Kesheng Technology (Stock Code: 688788) and Borui Pharmaceutical (Stock Code: 688166) have recent announcements regarding their stock activities[1] - A total of 30 companies have been flagged for abnormal trading activities, indicating potential market volatility[2]
万邦德振幅20.60%,3机构现身龙虎榜
Zheng Quan Shi Bao Wang· 2025-10-13 09:09
Core Insights - Wanbangde's stock price increased by 7.22% with a trading volume of 715 million yuan and a volatility of 20.60% on the day [2] - Institutional investors net bought 16.9968 million yuan while brokerage seats collectively net sold 30.9556 million yuan [2] - The stock has appeared on the "Dragon and Tiger List" seven times in the past six months, with an average price drop of 0.68% the day after and an average decline of 2.67% over the following five days [2] Trading Activity - The top five trading departments accounted for a total transaction volume of 277 million yuan, with a buying amount of 132 million yuan and a selling amount of 146 million yuan, resulting in a net sell of 13.9588 million yuan [2] - Three institutional special seats were involved in the trading, with a total buying amount of 54.1939 million yuan and a selling amount of 37.1971 million yuan, leading to a net buy of 16.9968 million yuan [2] Fund Flow - The stock experienced a net outflow of 4.1741 million yuan in main funds, with a significant outflow of 69.432 million yuan from large orders, while smaller orders saw a net inflow of 27.691 million yuan [2] - Over the past five days, the main funds have seen a net inflow of 122 million yuan [2]
万邦德(002082) - 关于股票交易异常波动的公告
2025-10-12 07:45
证券代码:002082 证券简称:万邦德 公告编号:2025-055 万邦德医药控股集团股份有限公司 关于股票交易异常波动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 万邦德医药控股集团股份有限公司(以下简称"公司")股票连续 3 个交易 日内(2025 年 9 月 30 日,2025 年 10 月 9 日,2025 年 10 月 10 日)收盘价格涨 幅偏离值累计超过 20%,根据《深圳证券交易所交易规则》的相关规定,属于股 票交易异常波动。 信息;公司前期披露的信息不存在需要更正、补充之处。 四、公司认为必要的风险提示 二、公司关注并核实的情况 针对公司股票异常波动情况,按照相关规定的要求,公司对有关事项进行了 核查,并询问了公司控股股东及实际控制人,现就核实情况说明如下: 1、公司前期披露的信息不存在需要更正、补充之处; 2、公司未发现近期公共媒体报道了可能或已经对本公司股票交易价格产生较 大影响的未公开重大信息; 3、公司目前经营情况正常,不存在内外部经营环境发生重大变化的情形; 4、公司、控股股东和实际控制人 ...
中药板块10月10日涨0.96%,万邦德领涨,主力资金净流入2.12亿元
Zheng Xing Xing Ye Ri Bao· 2025-10-10 08:46
Core Insights - The traditional Chinese medicine sector saw a rise of 0.96% on October 10, with Wanbangde leading the gains. In contrast, the Shanghai Composite Index fell by 0.94% and the Shenzhen Component Index dropped by 2.7% [1] Group 1: Market Performance - The closing price of Wanbangde was 13.43, with a significant increase of 9.99% and a trading volume of 268,400 shares, amounting to a transaction value of 347 million yuan [1] - Other notable performers included Tianmu Pharmaceutical, which closed at 19.15 with a 4.36% increase, and ST Xiangxue, which rose by 4.32% to close at 10.86 [1] - The overall trading volume for the traditional Chinese medicine sector was substantial, with individual stocks showing varied performance in terms of price changes and trading volumes [1] Group 2: Capital Flow - The traditional Chinese medicine sector experienced a net inflow of 212 million yuan from institutional investors, while retail investors saw a net outflow of 153 million yuan [2] - The capital flow data indicates that while some stocks attracted institutional investment, others faced significant selling pressure from retail investors [3] - Wanbangde had a net outflow of 64.05 million yuan from institutional investors, despite its price increase, indicating a complex market sentiment [3]
中药概念持续拉升,万邦德涨停,康芝药业、天目药业、珍宝岛、吉林敖东等跟涨。
Xin Lang Cai Jing· 2025-10-10 02:34
Group 1 - The Chinese medicine concept continues to rise, with Wanbangde hitting the daily limit, and companies such as Kangzhi Pharmaceutical, Tianmu Pharmaceutical, Zhenbaodao, and Jilin Aodong also experiencing gains [1]
创新药概念异动拉升
Di Yi Cai Jing Zi Xun· 2025-10-10 02:32
Core Viewpoint - The innovative drug concept has seen a significant surge in the market, with several companies experiencing notable stock price increases [1] Group 1: Company Performance - Changchun High-tech has risen over 8% [1] - Xinghao Pharmaceutical and Wanbangde have both increased by over 5% [1] - Other companies such as Tibet Pharmaceutical, Rongchang Bio, Xinlitai, Guangsheng Tang, and Nuocheng Jianhua have also shown upward movement in their stock prices [1]
中药板块9月30日跌0.28%,ST香雪领跌,主力资金净流出4.78亿元
Zheng Xing Xing Ye Ri Bao· 2025-09-30 08:42
Core Insights - The Chinese medicine sector experienced a slight decline of 0.28% on September 30, with ST Xiangxue leading the losses [1][2] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Xinbang Pharmaceutical (002390) with a closing price of 3.80, up 10.14% and a trading volume of 974,400 shares, totaling 361 million yuan [1] - Wanbangde (002082) closed at 66.11, up 10.00% with a trading volume of 216,600 shares, totaling 252 million yuan [1] - Other companies with positive performance included: - Jinhua Co. (600080) up 2.91% [1] - Zhongsheng Pharmaceutical (002317) up 1.83% [1] Fund Flow Analysis - The Chinese medicine sector saw a net outflow of 478 million yuan from institutional investors, while retail investors contributed a net inflow of 395 million yuan [2][3] - Key stocks with significant fund flow included: - Xinbang Pharmaceutical (002390) with a net inflow of 135 million yuan from institutional investors [3] - Zhongsheng Pharmaceutical (002317) with a net inflow of 57.69 million yuan [3] - Wanbangde (002082) with a net inflow of 53.26 million yuan [3]
669只股短线走稳 站上五日均线
Zheng Quan Shi Bao Wang· 2025-09-30 08:06
Market Overview - The Shanghai Composite Index closed at 3882.78 points, above the five-day moving average, with an increase of 0.52% [1] - The total trading volume of A-shares reached 2,197.249 billion yuan [1] Stocks Performance - A total of 669 A-shares broke through the five-day moving average today [1] - Stocks with significant deviation rates include: - Guolin Technology (国林科技) with a deviation rate of 14.86% and a daily increase of 20.00% [1] - Danghong Technology (当虹科技) with a deviation rate of 14.35% and a daily increase of 20.00% [1] - Bohai Automobile (渤海汽车) with a deviation rate of 7.78% and a daily increase of 9.91% [1] Detailed Stock Data - The following stocks showed notable performance: - Guolin Technology (300786): Latest price 19.86 yuan, five-day moving average 17.29 yuan, daily turnover rate 27.51% [1] - Danghong Technology (688039): Latest price 61.32 yuan, five-day moving average 53.63 yuan, daily turnover rate 12.32% [1] - Bohai Automobile (600960): Latest price 5.10 yuan, five-day moving average 4.73 yuan, daily turnover rate 3.40% [1] - Other stocks with positive performance include: - Huahua Co. (壶化股份) with a daily increase of 10.00% and a deviation rate of 7.57% [1] - Qingshang Co. (勤上股份) with a daily increase of 9.88% and a deviation rate of 7.50% [1]
万邦德(002082.SZ):在渐冻症领域布局了新药研发项目
Ge Long Hui· 2025-09-26 08:24
Core Insights - Wanbangde (002082.SZ) is advancing new drug development projects in the field of amyotrophic lateral sclerosis (ALS) and has secured core patent authorization for a differentiated MCR cyclic peptide in the metabolic field [1] Group 1 - The company has laid out new drug research projects specifically targeting ALS [1] - Wanbangde has achieved core patent authorization for its differentiated MCR cyclic peptide [1] - Both the ALS and metabolic projects are progressing steadily [1]
万邦德:在渐冻症领域布局了新药研发项目
Ge Long Hui· 2025-09-26 08:21
Core Viewpoint - Wanbangde (002082.SZ) is advancing its differentiated MCR cyclic peptide new drug in the metabolism field and has obtained core patent authorization, while also developing new drug projects in the field of amyotrophic lateral sclerosis (ALS) [1] Group 1 - The company has made significant progress in the metabolism sector with the development of a differentiated MCR cyclic peptide new drug [1] - Core patent authorization has been successfully obtained for the new drug in the metabolism field [1] - In the ALS sector, the company is actively pursuing new drug research and development projects [1]